Kaplan Fox Notifies Erasca, Inc. (ERAS) Investors of a Securities Class Action Deadline on August 10, 2026

Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit has been filed against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased or acquired Erasca securities between January 14, 2025, and April 26, 2026. Investors who have suffered losses are encouraged to contact Kaplan Fox by August 10, 2026, to potentially serve as lead plaintiff. The lawsuit alleges that Erasca made false and misleading statements and failed to disclose that its ERAS-0015 product's preclinical data was based on improper comparisons to Revolution Medicines, Inc. (RevMed), potentially violating patent and trade secret protections. This led to a stock price drop of nearly 11% on April 27, 2026, after Erasca disclosed it received a letter from RevMed's counsel alleging patent infringement and trade secret misappropriation.